Abstract
New oral anticoagulants (NOAC, anti-IIa or antiXa inhibitors) are as efficacious and as safe as "old" anticoagulants (heparin, low molecular weight heparin, vitamin K antagonists); moreover they present some advantages. Indeed, NOAC have a wide therapeutic window and do not require laboratory monitoring.
This review aims at answering in a brief and simplified manner to some questions.